Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Mol Genet Metab ; 114(4): 527-36, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25684057

RESUMO

Leukodystrophies are a heterogeneous, often progressive group of disorders manifesting a wide range of symptoms and complications. Most of these disorders have historically had no etiologic or disease specific therapeutic approaches. Recently, a greater understanding of the pathologic mechanisms associated with leukodystrophies has allowed clinicians and researchers to prioritize treatment strategies and advance research in therapies for specific disorders, some of which are on the verge of pilot or Phase I/II clinical trials. This shifts the care of leukodystrophy patients from the management of the complex array of symptoms and sequelae alone to targeted therapeutics. The unmet needs of leukodystrophy patients still remain an overwhelming burden. While the overwhelming consensus is that these disorders collectively are symptomatically treatable, leukodystrophy patients are in need of advanced therapies and if possible, a cure.


Assuntos
Doenças Desmielinizantes/terapia , Doenças Desmielinizantes Hereditárias do Sistema Nervoso Central/terapia , Leucodistrofia Metacromática/terapia , Leucoencefalopatias/terapia , Encefalopatias/prevenção & controle , Encefalopatias/terapia , Doenças Desmielinizantes/prevenção & controle , Doenças Desmielinizantes Hereditárias do Sistema Nervoso Central/prevenção & controle , Humanos , Leucodistrofia Metacromática/prevenção & controle , Leucoencefalopatias/prevenção & controle
2.
Science ; 262(5133): 533-8, 1993 Oct 22.
Artigo em Inglês | MEDLINE | ID: mdl-8211180

RESUMO

There has been considerable debate about the ethics of human germ-line gene modification. As a result of recent advances in the micromanipulation of embryos and the laboratory development of transgenic mice, a lively discussion has begun concerning both the technical feasibility and the ethical acceptability of human germ-line modification for the prevention of serious disease. This article summarizes some of the recent research on germ-line gene modification in animal models. Certain monogenic deficiency diseases that ultimately might be candidates for correction by germ-line intervention are identified. Several of the most frequently considered ethical issues relative to human germ-line gene modification are considered in the context of professional ethics, parental responsibility, and public policy. Finally, it is suggested that there is merit in continuing the discussion about human germ-line intervention, so that this technique can be carefully compared with alternative strategies for preventing genetic disease.


Assuntos
Blastocisto , Ética Médica , Técnicas de Transferência de Genes , Doenças Genéticas Inatas/prevenção & controle , Terapia Genética , Células Germinativas , Experimentação Animal , Animais , Beneficência , Diversidade Cultural , Neoplasias Oculares/prevenção & controle , Saúde , Humanos , Síndrome de Lesch-Nyhan/prevenção & controle , Leucodistrofia Metacromática/prevenção & controle , Seleção de Pacientes , Autonomia Pessoal , Retinoblastoma/prevenção & controle , Medição de Risco , Responsabilidade Social , Doença de Tay-Sachs/prevenção & controle
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...